T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis

T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis

Immune responses in people with multiple sclerosis (pwMS) receiving disease-modifying therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-targeting immunotherapies, including anti-CD20 treatments and sphingosine-1-phosphate receptor (S1PR) modulators, atte...

Full description

Bibliographic Details
Main Authors: Asia-Sophia Wolf, Anthony Ravussin, Marton König, Mathias H. Øverås, Guri Solum, Ingrid Fadum Kjønstad, Adity Chopra, Trygve Holmøy, Hanne F. Harbo, Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Einar August Høgestøl, Jon Torgils Vaage, Elisabeth G. Celius, Fridtjof Lund-Johansen, Ludvig A. Munthe, Gro Owren Nygaard, Siri Mjaaland
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-06-01
Series:JCI Insight
Subjects:
COVID-19
Immunology
Online Access:https://doi.org/10.1172/jci.insight.165111

Internet

https://doi.org/10.1172/jci.insight.165111

Similar Items